GlassScriptPhysician profile
Sanjay Taneja
NPI 1144315367
$5,627.92
in general payments reported to CMS, 2019-2025
34 companies · $926 in 2025
The $926 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $167 · 2021: $681 · 2022: $664 · 2023: $1,178 · 2024: $1,313 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,172.72 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $803.76 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $610.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $563.01 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $470.83 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.34 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $213.18 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $162.50 | 2019-2020 | |
| Esperion Therapeutics, INC. | $159.95 | 2021-2025 | Nexletol |
| Abbott Laboratories | $152.24 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $124.97 | 2023 | Auvelity |
| Amgen INC. | $111.00 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $102.54 | 2019-2021 | |
| Pfizer INC. | $92.50 | 2019-2024 | |
| Exact Sciences Corporation | $57.39 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $52.96 | 2024 | Veozah |
| Sanofi Pasteur INC. | $51.48 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $47.17 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $34.66 | 2021-2023 | Rexulti |
| Seqirus USA INC | $33.26 | 2019-2024 | Flucelvax, Fluad |
| Renalytix Ai, INC. | $32.61 | 2022 | |
| Ibsa Pharma INC. | $31.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.00 | 2019-2020 | |
| Dexcom, INC. | $24.76 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $22.98 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $22.85 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.16 | 2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $17.92 | 2022 | |
| Verona Pharma, INC. | $17.26 | 2025 | Ohtuvayre |
| Eisai INC. | $15.50 | 2021 | |
| Horizon Therapeutics Plc | $14.04 | 2021 | |
| Allergan, INC. | $13.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Taneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.